This page has only limited features, please log in for full access.

Unclaimed
Ashwini Malla
Plant Genetic Engineering Laboratory, Department of Biotechnology, Bharathiar University, Coimbatore, Tamil Nadu 641 046, India

Basic Info

Basic Info is private.

Honors and Awards

The user has no records in this section


Career Timeline

The user has no records in this section.


Short Biography

The user biography is not available.
Following
Followers
Co Authors
The list of users this user is following is empty.
Following: 0 users

Feed

Journal article
Published: 29 December 2020 in Plants
Reads 0
Downloads 0

Isoflavonoids, the diverse group of secondary metabolites derived from the phenylpropanoid pathway, are distributed predominantly in leguminous plants and play a vital role in promoting human health. Genetic engineering of the metabolite synthesis pathway has turned out to be an attractive approach for the production of various secondary metabolites. In our study, we attempted to produce the isoflavone genistein, a well-known health-promoting metabolite, in Allium cepa L. (onion) by introducing Glycine max Isoflavone synthase (GmIFS). The GmIFS gene was cloned into the pEarleyGate 102 HA vector and transformed into onion by Agrobacterium-mediated and biolistic methods. The presence of GmIFS in transgenic onion was confirmed by PCR, dot blot, and Southern hybridization. Analysis of the transgenic onion calli lines demonstrated that the expression of the GmIFS gene led to the production of isoflavone genistein in in vitro tissues. The biolistic stable transformed calli with transformation efficiency of 73% (62.65 nM/g FW) accumulated more genistein than the Agrobacterium stable transformed calli with transformation efficiency of 56% (42.5 nM/g FW). Overall, heterologous gene expression of GmIFS was demonstrated by modifying the secondary metabolite pathway in onion tissues for the production of isoflavone genistein that can boost up human health with its health-promoting properties.

ACS Style

Ashwini Malla; Balamurugan Shanmugaraj; Balamurugan Srinivasan; Ashutosh Sharma; Sathishkumar Ramalingam. Metabolic Engineering of Isoflavonoid Biosynthesis by Expressing Glycine max Isoflavone Synthase in Allium cepa L. for Genistein Production. Plants 2020, 10, 52 .

AMA Style

Ashwini Malla, Balamurugan Shanmugaraj, Balamurugan Srinivasan, Ashutosh Sharma, Sathishkumar Ramalingam. Metabolic Engineering of Isoflavonoid Biosynthesis by Expressing Glycine max Isoflavone Synthase in Allium cepa L. for Genistein Production. Plants. 2020; 10 (1):52.

Chicago/Turabian Style

Ashwini Malla; Balamurugan Shanmugaraj; Balamurugan Srinivasan; Ashutosh Sharma; Sathishkumar Ramalingam. 2020. "Metabolic Engineering of Isoflavonoid Biosynthesis by Expressing Glycine max Isoflavone Synthase in Allium cepa L. for Genistein Production." Plants 10, no. 1: 52.

Review
Published: 04 September 2020 in Molecules
Reads 0
Downloads 0

The emergence of the Coronavirus Disease 2019 (COVID-19) caused by the SARS-CoV-2 virus has led to an unprecedented pandemic, which demands urgent development of antiviral drugs and antibodies; as well as prophylactic approaches, namely vaccines. Algae biotechnology has much to offer in this scenario given the diversity of such organisms, which are a valuable source of antiviral and anti-inflammatory compounds that can also be used to produce vaccines and antibodies. Antivirals with possible activity against SARS-CoV-2 are summarized, based on previously reported activity against Coronaviruses or other enveloped or respiratory viruses. Moreover, the potential of algae-derived anti-inflammatory compounds to treat severe cases of COVID-19 is contemplated. The scenario of producing biopharmaceuticals in recombinant algae is presented and the cases of algae-made vaccines targeting viral diseases is highlighted as valuable references for the development of anti-SARS-CoV-2 vaccines. Successful cases in the production of functional antibodies are described. Perspectives on how specific algae species and genetic engineering techniques can be applied for the production of anti-viral compounds antibodies and vaccines against SARS-CoV-2 are provided.

ACS Style

Sergio Rosales-Mendoza; Ileana García-Silva; Omar González-Ortega; José M. Sandoval-Vargas; Ashwini Malla; Sornkanok Vimolmangkang. The Potential of Algal Biotechnology to Produce Antiviral Compounds and Biopharmaceuticals. Molecules 2020, 25, 4049 .

AMA Style

Sergio Rosales-Mendoza, Ileana García-Silva, Omar González-Ortega, José M. Sandoval-Vargas, Ashwini Malla, Sornkanok Vimolmangkang. The Potential of Algal Biotechnology to Produce Antiviral Compounds and Biopharmaceuticals. Molecules. 2020; 25 (18):4049.

Chicago/Turabian Style

Sergio Rosales-Mendoza; Ileana García-Silva; Omar González-Ortega; José M. Sandoval-Vargas; Ashwini Malla; Sornkanok Vimolmangkang. 2020. "The Potential of Algal Biotechnology to Produce Antiviral Compounds and Biopharmaceuticals." Molecules 25, no. 18: 4049.

Review
Published: 22 February 2020 in Pathogens
Reads 0
Downloads 0

Novel Coronavirus (2019-nCoV) is an emerging pathogen that was first identified in Wuhan, China in late December 2019. This virus is responsible for the ongoing outbreak that causes severe respiratory illness and pneumonia-like infection in humans. Due to the increasing number of cases in China and outside China, the WHO declared coronavirus as a global health emergency. Nearly 35,000 cases were reported and at least 24 other countries or territories have reported coronavirus cases as early on as February. Inter-human transmission was reported in a few countries, including the United States. Neither an effective anti-viral nor a vaccine is currently available to treat this infection. As the virus is a newly emerging pathogen, many questions remain unanswered regarding the virus’s reservoirs, pathogenesis, transmissibility, and much more is unknown. The collaborative efforts of researchers are needed to fill the knowledge gaps about this new virus, to develop the proper diagnostic tools, and effective treatment to combat this infection. Recent advancements in plant biotechnology proved that plants have the ability to produce vaccines or biopharmaceuticals rapidly in a short time. In this review, the outbreak of 2019-nCoV in China, the need for rapid vaccine development, and the potential of a plant system for biopharmaceutical development are discussed.

ACS Style

Balamurugan Shanmugaraj; Ashwini Malla; Waranyoo Phoolcharoen. Emergence of Novel Coronavirus 2019-nCoV: Need for Rapid Vaccine and Biologics Development. Pathogens 2020, 9, 148 .

AMA Style

Balamurugan Shanmugaraj, Ashwini Malla, Waranyoo Phoolcharoen. Emergence of Novel Coronavirus 2019-nCoV: Need for Rapid Vaccine and Biologics Development. Pathogens. 2020; 9 (2):148.

Chicago/Turabian Style

Balamurugan Shanmugaraj; Ashwini Malla; Waranyoo Phoolcharoen. 2020. "Emergence of Novel Coronavirus 2019-nCoV: Need for Rapid Vaccine and Biologics Development." Pathogens 9, no. 2: 148.